XJPX
7079
Market cap39mUSD
Oct 09, Last price
2,610.00JPY
1D
0.73%
1Q
0.04%
IPO
-17.67%
Name
WDB coco Co Ltd
Chart & performance
P/E
9.24
P/S
1.30
EPS
282.47
Div yield, %
3.09%
Shrs. gr., 5y
0.42%
Rev. gr., 5y
13.38%
Revenues
4.82b
-9.59%
Net income
679m
-25.59%
CFO
571m
-48.33%
Dividend
Mar 30, 2027100 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
WDB coco Co., Ltd. offers specialized contractual services to pharmaceutical companies throughout Japan. The firm plays a crucial role in advancing pharmaceuticals and medical devices, with a particular focus on safety information management, support for safety data systems, clinical research assistance, and post-market safety operations. Its offerings also encompass translation and quality control document preparation, additional clinical study support, and personnel dispatch. Furthermore, WDB coco provides comprehensive post-marketing surveillance (PMS) solutions, which include securing agreements with healthcare facilities, explaining survey protocols, collecting survey forms, conducting detailed monitoring (like re-surveys), managing a central case registration center, handling data, and performing statistical analyses. Established in 1984, the company's headquarters are located in Tokyo, Japan.
Key people
Hatsune Nishimori
Director of Contract Sales, Director · since 2020
Motoyuki Fujiwara
Chief Director of Administration, Director · since 2021
Director · since 2011
Haruhiko Taniguchi
President, Representative Director · since 2014
Masashi Ooi
Independent Director · since 2020
Kenta Yokogawa
Independent Director · since 2019
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||